{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["122(10)"],"submitter":["Carmona-Bayonas A"],"funding":["Leo Pharma Rovi","BMS-Pfizer","Sanofi"],"pubmed_abstract":["<h4>Background</h4> Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated.<h4>Methods</h4> The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients.<h4>Results</h4> In total, 1,536 subjects were evaluated; 58.4% (<i>n</i> = 894) had a PE and 7% (<i>n</i> = 108) received antiangiogenic therapy (bevacizumab in 75%"],"journal":["Thrombosis and haemostasis"],"pagination":["1653-1661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9512585"],"repository":["biostudies-literature"],"pubmed_title":["Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial."],"pmcid":["PMC9512585"],"pubmed_authors":["Fernandez Perez I","Perez Segura P","Gomez D","Ortega L","Garcia Perez E","Garcia de Herreros M","Obispo Portero B","Agnelli G","Martinez Del Prado P","M Brozos E","Munoz A","Pachon Olmos V","Verso M","Jimenez-Fonseca P","Teijeira Sanchez L","Rubio Perez J","Carmona-Bayonas A","Hernandez Perez C","Serrano Moyano M","Sanchez Canovas M","David Cumplido Buron J","Martinez Lago N","Antonio Rebollo M","Quintanar Verduguez T","Munoz Langa J","Martinez de Castro E","Biosca M"],"additional_accession":[]},"is_claimable":false,"name":"Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.","description":"<h4>Background</h4> Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated.<h4>Methods</h4> The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients.<h4>Results</h4> In total, 1,536 subjects were evaluated; 58.4% (<i>n</i> = 894) had a PE and 7% (<i>n</i> = 108) received antiangiogenic therapy (bevacizumab in 75%","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-21T20:07:54.214Z","creation":"2025-04-05T17:53:27.911Z"},"accession":"S-EPMC9512585","cross_references":{"pubmed":["35381615"],"doi":["10.1055/a-1816-8347"]}}